limula biotech
Limula Biotech is a Swiss company that builds automated, closed hardware platforms combining a bioreactor and centrifuge (LimONE and LimGROW) for manufacturing personalized cell and gene therapies. It sells to cell therapy manufacturers, allogeneic developers, CDMOs, and pharmaceutical companies via an early-access enterprise model.
- Company typePrivate
- Founded-
- HeadquartersLausanne, Switzerland
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What limula biotech does
Limula Biotech (legal entity: Limula SA) is a Swiss biotechnology company headquartered at Biopôle StartLab in Lausanne, Switzerland, that develops automated hardware platforms for the manufacturing of personalized cell and gene therapies. The company's defining technical innovation is a proprietary platform that combines a bioreactor and a centrifuge into a single closed device, enabled by in-situ centrifugation — a capability that allows complex cell processing steps to be sequenced in one container without human intervention. Limula's commercial product portfolio consists of two offerings: LimONE, an automated all-in-one closed system for cell processing, and LimGROW, a scalable bioreactor supporting both process development (scale-down) and commercial manufacturing (scale-up/scale-out).
The platform is designed to serve four customer segments: cell therapy manufacturers producing autologous therapies (T cells, hematopoietic stem cells), allogeneic cell therapy developers, contract development and manufacturing organizations (CDMOs), and pharmaceutical companies. Limula pursues a partnership-driven, enterprise sales motion — offering Early Access Programs to selected partners with compelling use cases — and engages stakeholders across the broader Cell & Gene Therapy value chain. Revenue mechanics are anchored on hardware/platform sales (LimONE, LimGROW), recurring single-use consumables, integrated software for process control and user experience, and collaborative partnership agreements, with quote-based enterprise pricing and multi-year contracts. The company maintains no publicly disclosed pricing, revenue figures, or funding rounds.
Limula markets through content (website, downloadable white papers, posters, application notes), conference participation (ISCT, ESGCT, Basel Cell Symposium, AdvT), a quarterly newsletter, and direct partner outreach. The company has assembled an ecosystem of approximately 26 supporting partner organizations since 2020 and is actively hiring engineers and biologists while soliciting new investors. No management team, board, funding history, revenue, headcount, or patents are disclosed in available sources, and the company is classified as pre-commercial or early commercial.
limula biotech firmographics
Firmographics- Name
- limula biotech
- Legal name
- Limula SA
- Website
- https://limula-biotech.com
- Company type
- Private
- Operating status
- Operating
- Short description
- Limula Biotech is a Swiss company that builds automated, closed hardware platforms combining a bioreactor and centrifuge (LimONE and LimGROW) for manufacturing personalized cell and gene therapies. It sells to cell therapy manufacturers, allogeneic developers, CDMOs, and pharmaceutical companies via an early-access enterprise model.
- Ownership category
- akta.pro rank
limula biotech industry classification
Industry- Product category
- Cell Therapy Manufacturing Equipment
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
- akta.pro secondary industries
- Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG)
Keywords
Where limula biotech is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
limula biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Hardware/Platform Sales: Sale of LimOne and LimGROW automated manufacturing platforms combining bioreactor and centrifuge technology for cell and gene therapy production
- Consumables: Single-use consumables for the closed automated platform, enabling cell processing in a single container
- Software: Software component integrated into the automated platform for intuitive user experience and process control
- Partnership/Early Access Programs: Early access to technology offered to selected partners with exciting use cases; collaborative partnerships for technology adoption
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based enterprise pricing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
limula biotech product offering
Product offeringCore offering
Limula Biotech develops and manufactures automated, all-in-one closed platforms for cell and gene therapy manufacturing. Its proprietary hardware combines a bioreactor and a centrifuge into a single device using in-situ centrifugation, enabling complex cell processing steps to be sequenced in one container without human intervention. The portfolio includes the LimONE automated closed manufacturing platform and the LimGROW scalable bioreactor for cell growth and expansion, sold to cell therapy developers, CDMOs, and pharmaceutical companies.
Product overview
Limula offers a unified platform for cell and gene therapy manufacturing across scales. The portfolio consists of two core products: LimONE, an automated all-in-one closed system combining bioreactor and centrifuge capabilities for cell processing; and LimGROW, a scalable bioreactor for process development and commercial manufacturing. Both products leverage proprietary in-situ centrifugation technology to enable automated, closed, and versatile cell therapy manufacturing with minimal human intervention.
Differentiator
Problem solved
Functional benefit
Brands
- LimOne: Automated closed platform for cell therapy manufacturing combining bioreactor and centrifuge capabilities.
- LimGROW
Products and services
- LimONE
Quantifiable outcome
- Low hands-on time compared to existing cell therapy manufacturing solutions
- +4 more outcomes
Companies that use limula biotech
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
limula biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
limula biotech partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Various Partner OrganizationscoreLimula has received support from numerous partner organizations since 2020, though specific partner names are not individually listed in the text. The company logo section displays approximately 26 partner organization logos including StartLab, Biopôle, and various other industry organizations supporting the company's development.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
limula biotech competitors and assessment
Company assessmentDirect peers
- Miltenyi Biotec: Established manufacturer of cell processing instruments, reagents, and closed automation systems (e.g., Prodigy) used by cell therapy developers and CDMOs. Directly comparable to Limula as a hardware-plus-consumables platform for autologous and allogeneic cell therapy manufacturing.
- Cellares: Developer of automated, closed, factory-in-a-box cell therapy manufacturing platforms (Cell Shuttle) targeting pharma and CDMO customers. Closely aligned with Limula's positioning of an end-to-end automated, scalable cell therapy manufacturing solution.
- Terumo BCT: Supplier of cell processing, centrifugation, and blood component technologies including the Quantum and Elutra cell expansion systems. Directly comparable for cell therapy manufacturers seeking closed, automated processing hardware.
Broad incumbents
- Cytiva: Global bioprocessing supplier of bioreactors, single-use systems, and cell therapy workflow tools. Comparable as a broad incumbent providing the equipment ecosystem that cell therapy manufacturers rely on, even if not a single-vessel automated platform like Limula.
- Lonza: Global CDMO and bioprocessing technology provider with deep cell and gene therapy manufacturing capabilities. Relevant as both a potential customer (using Limula's platform) and as an incumbent defining current manufacturing standards.
- Sartorius: Major bioprocessing equipment and consumables supplier serving cell and gene therapy manufacturers with bioreactors and process solutions. Comparable as a broad incumbent that Limula's platform would either complement or compete against.
- Thermo Fisher Scientific: Global life sciences leader providing cell therapy manufacturing tools, reagents, and CDMO services through its Patheon and PPD units. Comparable as an incumbent whose cell therapy workflow products overlap with Limula's automation platform.
- Fresenius Kabi: Provider of cell therapy manufacturing solutions, including the Lovo cell processing platform and adjacent bioprocessing products. Comparable as an established supplier of automated cell processing systems to cell therapy developers.
Emerging players
- Multiply Labs: Developer of robotic and automated manufacturing platforms for cell therapies and other advanced biologics. Comparable as a newer entrant pursuing closed, automated cell therapy manufacturing in competition with Limula.
- Ori Biotech: Developer of an automated, closed cell and gene therapy manufacturing platform targeting scalability and process standardization. Comparable as a direct emerging competitor with similar positioning to Limula.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
limula biotech social profiles
Digital presencelimula biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
limula biotech leadership team
Management profileNumber of profiles
limula biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
limula biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about limula biotech
What does limula biotech do?
Limula Biotech develops and manufactures automated, all-in-one closed platforms for cell and gene therapy manufacturing. Its proprietary hardware combines a bioreactor and a centrifuge into a single device using in-situ centrifugation, enabling complex cell processing steps to be sequenced in one container without human intervention. The portfolio includes the LimONE automated closed manufacturing platform and the LimGROW scalable bioreactor for cell growth and expansion, sold to cell therapy developers, CDMOs, and pharmaceutical companies.
Is limula biotech a public or private company?
limula biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was limula biotech founded?
limula biotech was founded in -1.
Where is limula biotech based?
limula biotech is headquartered in Lausanne, Switzerland, in the Europe region.
How does limula biotech make money?
Four revenue lines are on record. Hardware/Platform Sales are the primary driver. The others are consumables, software and partnership/Early Access Programs.
Who are limula biotech's main competitors?
Direct peers on record are Miltenyi Biotec, Cellares and Terumo BCT. Broad incumbents are Cytiva, Lonza, Sartorius, Thermo Fisher Scientific and Fresenius Kabi. Emerging players are Multiply Labs and Ori Biotech.
Does limula biotech have an API?
No public API is recorded for limula biotech.
What industry is limula biotech in?
limula biotech's product category is Cell Therapy Manufacturing Equipment. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 3391 and its SIC code is 3841.